Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. 4D Molecular Therapeutics, Inc.
  6. News
  7. Summary
    FDMT   US35104E1001

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
7.810 USD   +5.97%
05/13SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps Outperform Rating
MT
05/124D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/124D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics : Evercore ISI Starts 4D Molecular Therapeutics at Outperform With $70 Price Target

01/05/2021 | 08:29am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
05/13SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps O..
MT
05/124D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
AQ
05/124D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/12Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Posts Q1 Revenue $1.2M
MT
05/124D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Cor..
GL
05/124D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Cor..
AQ
05/10TRANSCRIPT : 4D Molecular Therapeutics, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/054D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Confere..
GL
05/054D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Confere..
AQ
04/044D Molecular Therapeutics Starts Cystic Fibrosis Trial with Dosing of First Patient
MT
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 15,0 M - -
Net income 2022 -84,7 M - -
Net cash 2022 47,1 M - -
P/E ratio 2022 -2,59x
Yield 2022 -
Capitalization 252 M 252 M -
EV / Sales 2022 13,7x
EV / Sales 2023 18,5x
Nbr of Employees 137
Free-Float 88,3%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,81 $
Average target price 28,25 $
Spread / Average Target 262%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-64.40%252
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567